Compare NFE & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NFE | GRML |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6M | 29.2M |
| IPO Year | 2018 | 2022 |
| Metric | NFE | GRML |
|---|---|---|
| Price | $3.51 | $5.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 413.9K | ★ 6.0M |
| Earning Date | 11-20-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,504,037,000.00 | N/A |
| Revenue This Year | $108.26 | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.16 |
| 52 Week High | $16.90 | $18.21 |
| Indicator | NFE | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 40.06 | 47.10 |
| Support Level | $0.40 | $0.28 |
| Resistance Level | $7.13 | $7.53 |
| Average True Range (ATR) | 0.41 | 0.85 |
| MACD | -0.25 | -0.28 |
| Stochastic Oscillator | 3.42 | 34.48 |
New Fortress Energy Inc is an integrated gas-to-power company. It owns and operates natural gas and liquefied natural gas (LNG) infrastructure, and an integrated fleet of ships and logistics assets to deliver turnkey energy solutions to markets globally. The company's reportable segments are: Terminals and Infrastructure, and Ships. Maximum revenue is generated from the Terminals and Infrastructure segment, which includes vertically integrated gas-to-power solutions, spanning the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, facilities, and conversion or development of natural gas-fired power generation. Vessels that are utilized in the company's terminal, logistics, or sub-charter operations are included in this segment.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.